Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision

Simply Wall St.04-04

AdvertisementWhy Luye Pharma’s latest earnings matter for investors Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625150576?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-04 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625150576","market":"nz","top_or_hot":-1,"title":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Luye Pharma’s latest earnings matter for investors Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-04 22:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Luye Pharma’s latest earnings matter for investors Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a","article_id":"2625150576","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625150576","pubTimestamp":1775312322,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Luye Pharma’s latest earnings matter for investors\nLuye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income alongside a decision not to declare a 2025 dividend.\nThe company reported sales of CN¥6,308.37 million for 2025, compared with CN¥6,061.44 million a year earlier. Net income came in at CN¥618.75 million, up from CN¥471.89 million, while basic earnings per share from continuing operations were CN¥0.1588...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1606":"中医药概念","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02186":"绿叶制药","BK1583":"高瓴概念"},"translate_title":"绿叶制药集团（SEHK：2186）盈利增长和2025年意外股息决定后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02186":0.9},"content_text":"AdvertisementWhy Luye Pharma’s latest earnings matter for investors Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income alongside a decision not to declare a 2025 dividend. The company reported sales of CN¥6,308.37 million for 2025, compared with CN¥6,061.44 million a year earlier. Net income came in at CN¥618.75 million, up from CN¥471.89 million, while basic earnings per share from continuing operations were CN¥0.1588 versus CN¥0.1254. See our latest analysis for Luye Pharma Group. At a share price of HK$2.92, Luye Pharma’s recent full year results have coincided with a 21.16% 30 day share price return and a 37.09% 1 year total shareholder return, although the 3 year and 5 year total shareholder returns remain negative. If earnings news has you rethinking where growth could come from next, this can be a good moment to scan other opportunities using the 125 healthcare AI stocks. With Luye Pharma trading at HK$2.92, alongside strong recent share price gains and no dividend on offer, the key question is whether the current level still offers meaningful upside or whether the market is already pricing in future growth. Price-to-Earnings of 25.8x: Is it justified? Luye Pharma is trading on a P/E of 25.8x, which sits above both its industry average and its own estimated fair P/E level, even after a strong recent share price run to HK$2.92. The P/E ratio compares the current share price with earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a company in pharmaceuticals, a higher P/E can sometimes reflect expectations of stronger future earnings or confidence in a product pipeline, while a lower P/E can point to more cautious expectations. Here, the P/E of 25.8x is higher than the Hong Kong pharmaceuticals industry average of 15.4x, which suggests the market is placing a richer price on Luye Pharma’s earnings than on its sector peers. It also sits above the estimated fair P/E of 23.9x, a level the market could move towards if sentiment or earnings expectations change, even though it remains below the peer average of 27.6x. Explore the SWS fair ratio for Luye Pharma Group Result: Price-to-Earnings of 25.8x (OVERVALUED) However, recent negative 3 year and 5 year total shareholder returns, as well as the decision not to declare a 2025 dividend, could quickly cool current optimism. Find out about the key risks to this Luye Pharma Group narrative. Another view: Cash flows paint a different picture While the P/E of 25.8x makes Luye Pharma look expensive relative to the Hong Kong pharmaceuticals industry and its own fair ratio, the SWS DCF model tells a different story. At HK$2.92, the share price sits well below the model’s fair value estimate of HK$13.19, which implies a wide gap between what cash flows suggest and what the market is currently willing to pay. For you, the question is whether that gap signals opportunity or justifies caution. Look into how the SWS DCF model arrives at its fair value. 2186 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Luye Pharma Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 247 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With mixed signals on value, risk and growth potential, it makes sense to review the numbers yourself and decide where you stand. If you want a concise snapshot of the main concerns and potential upsides highlighted by the data, take a look at the 2 key rewards and 1 important warning sign Looking for more investment ideas? If Luye Pharma has sharpened your focus on value and risk, do not stop here. Use the screeners below to quickly spot other opportunities that might suit your plan.  Target stronger pricing power by checking companies that screen well on earnings quality and valuation through the 247 high quality undervalued stocks. Prioritise resilience by reviewing companies that clear strict balance sheet and fundamentals filters using the solid balance sheet and fundamentals stocks screener (385 results). Get ahead of the crowd by scanning a screener containing 589 high quality undiscovered gems before they land on everyone else's radar.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625150576","isCrawlerRequest":true}